Page 1 | Search Results | Blood Advances | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

The odyssey of pacritinib in myelofibrosis

Sangeetha Venugopal, John Mascarenhas

Blood Adv (2022) 6 (16): 4905–4913.

https://doi.org/10.1182/bloodadvances.2022007524

Published: 2022

Journal Articles

Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies

Anand A. Patel, Kirk Cahill, Caner Saygin, Olatoyosi Odenike

Blood Adv (2021) 5 (8): 2264–2271.

https://doi.org/10.1182/bloodadvances.2020002929

Published: 2021

Journal Articles

Treating lymphoma is now a bit EZ-er

Ryan D. Morin, Sarah E. Arthur, Sarit Assouline

Blood Adv (2021) 5 (8): 2256–2263.

https://doi.org/10.1182/bloodadvances.2020002773

Published: 2021

Journal Articles

Development of luspatercept to treat ineffective erythropoiesis

Anne Sophie Kubasch, Pierre Fenaux, Uwe Platzbecker

Blood Adv (2021) 5 (5): 1565–1575.

https://doi.org/10.1182/bloodadvances.2020002177

Published: 2021

Journal Articles

The use of luspatercept for thalassemia in adults

Maria Domenica Cappellini, Ali T. Taher

Blood Adv (2021) 5 (1): 326–333.

https://doi.org/10.1182/bloodadvances.2020002725

Published: 2021

Journal Articles

C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas

Caron A. Jacobson, Marcela V. Maus

Blood Adv (2020) 4 (22): 5858–5862.

https://doi.org/10.1182/bloodadvances.2020003391

Published: 2020

Journal Articles

Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

Naveen Pemmaraju, Marina Konopleva

Blood Adv (2020) 4 (16): 4020–4027.

https://doi.org/10.1182/bloodadvances.2019000173

Published: 2020

Journal Articles

The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease

Robert Zeiser, Gérard Socié

Blood Adv (2020) 4 (15): 3789–3794.

https://doi.org/10.1182/bloodadvances.2020002097

Published: 2020

Journal Articles

Fedratinib in myelofibrosis

Ann Mullally, John Hood, Claire Harrison, Ruben Mesa

Blood Adv (2020) 4 (8): 1792–1800.

https://doi.org/10.1182/bloodadvances.2019000954

Published: 2020

Journal Articles

Gilteritinib: potent targeting of FLT3 mutations in AML

Mark Levis, Alexander E. Perl

Blood Adv (2020) 4 (6): 1178–1191.

https://doi.org/10.1182/bloodadvances.2019000174

Published: 2020

Journal Articles

Venetoclax for AML: changing the treatment paradigm

Daniel A. Pollyea, Maria Amaya, Paolo Strati, Marina Y. Konopleva

Blood Adv (2019) 3 (24): 4326–4335.

https://doi.org/10.1182/bloodadvances.2019000937

Published: 2019

Journal Articles

Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice

Cindy E. Neunert, Melissa J. Rose

Blood Adv (2019) 3 (12): 1907–1915.

https://doi.org/10.1182/bloodadvances.2019000279

Published: 2019

Journal Articles

Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia

Joseph Wynne, David Wright, Wendy Stock

Blood Adv (2019) 3 (1): 96–104.

https://doi.org/10.1182/bloodadvances.2018026211

Published: 2019

Journal Articles

How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD

Samantha M. Jaglowski, Bruce R. Blazar

Blood Adv (2018) 2 (15): 2012–2019.

https://doi.org/10.1182/bloodadvances.2018013060

Published: 2018

Journal Articles

The use of defibrotide in blood and marrow transplantation

Paul G. Richardson, Enric Carreras, Massimo Iacobelli, Bijan Nejadnik

Blood Adv (2018) 2 (12): 1495–1509.

https://doi.org/10.1182/bloodadvances.2017008375

Published: 2018

Journal Articles

Eltrombopag for use in children with immune thrombocytopenia

Taylor Olmsted Kim, Jenny Despotovic, Michele P. Lambert

Blood Adv (2018) 2 (4): 454–461.

https://doi.org/10.1182/bloodadvances.2017010660

Published: 2018

Journal Articles

Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis

Richard M. Stone, Paul W. Manley, Richard A. Larson, Renaud Capdeville

Blood Adv (2018) 2 (4): 444–453.

https://doi.org/10.1182/bloodadvances.2017011080

Published: 2018

Journal Articles

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma

Reid W. Merryman, Philippe Armand, Kyle T. Wright, Scott J. Rodig

Blood Adv (2017) 1 (26): 2643–2654.

https://doi.org/10.1182/bloodadvances.2017012534

Published: 2017

NARROW

The odyssey of pacritinib in myelofibrosis

Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies

Treating lymphoma is now a bit EZ-er

Development of luspatercept to treat ineffective erythropoiesis

The use of luspatercept for thalassemia in adults

C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas

Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm

The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease

Fedratinib in myelofibrosis

Gilteritinib: potent targeting of FLT3 mutations in AML

Venetoclax for AML: changing the treatment paradigm

Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice

Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia

How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD

The use of defibrotide in blood and marrow transplantation

Eltrombopag for use in children with immune thrombocytopenia

Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only